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Abstract 
The angiogenic microenvironment has been known to be a component of angioimmunoblastic T-
cell lymphoma since its initial characterization. We have shown that angioimmunoblastic T-cell 
lymphoma endothelial cells produce vascular endothelial growth factor-A (VEGFA), and 
participate in lymphoma progression. In squamous cell carcinoma, endothelial BCL2 expression 
induces a cross-talk with tumor cells through VEGFA, a major mediator of tumoral angiogenesis. 
In the present study, we analyzed BCL2 and VEGFA in 30 angioimmunoblastic T-cell lymphomas, 
using triple immunofluorescence to identify protein co-expression in well-characterized lymphoma 
cells and microenvironment neoangiogenic endothelial cells. Using quantitative real-time-PCR, we 
assessed mRNA expression levels in laser-microdissected endothelial and lymphoma cells. 
In lymphoma cells, as in endothelial cells, BCL2 and VEGFA proteins were co-expressed. BCL2 
was expressed only in neoangiogenic CD34
+
CD105
+
 endothelial cells. In laser-microdissected cells, 
mRNA studies showed a significant relationship between BCL2 and VEGFA levels in CD34
+
 
endothelial cells, but not in CD3
+
CD10
+
lymphoma cells, or in CD34
+
 endothelial cells from lymph 
node hyperplasia. Further study showed that, in AITL, BCL2 mRNA levels in CD34
+
CD105
+
 
neoangiogenic endothelial cells also correlated with microvessel density, International Prognostic 
Index, Ann Arbor stage, bone marrow involvement and elevated LDH. 
BCL2 expression by CD105
+
 neoangiogenic endothelial cells is related to tumor progression in 
angioimmunoblastic T-cell lymphoma. 
 
Keywords: Angioimmunolbastic T-Cell Lyphoma, BCL2, CD105, endothelial cell, 
neoangiogenesis, VEGF 
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Introduction 
The angiogenic microenvironment has been known to be a component of angioimmunoblastic T-
cell lymphoma since its initial characterization 1-2. We have shown that endothelial cells in invasive 
areas of angioimmunoblastic T-cell lymphoma produce vascular endothelial growth factor-A 
(VEGFA), and participate in tumor progression by an autocrine effect involving the VEGF-R1 
receptor 3. The importance of highlighting the association of VEGFA with angioimmunoblastic T-
cell lymphoma is its potential role for anti-angiogenic therapy in this disease 4-7.  
In oral squamous cell carcinoma, a crosstalk between endothelial and tumor cells mediated by 
BCL2 through VEGF and its receptors has been recently identified 8. In a murine model of 
xenografted human squamous cell carcinoma cell lines, BCL2-transfected endothelial cells 
increase: i) tumor growth 8, ii) tumor invasion, as measured on matrigel, and iii) lung metastases 
number 9. In this model, BCL2 expression by endothelial cells of tumor areas induces VEGFA 
overexpression by the same endothelial cells.  
Hypoxia can also induce BCL2 expression in human aortic endothelial cells through p38 MAPK 
pathway 10. In vitro, BCL2 expression is able to protect human dermal endothelial cells from 
apoptosis, independently of cytochrome c release, by increasing survivin expression, and inhibiting 
p53 and p38 MAPK accumulation 11. Moreover, blocking BCL2 activity alters in vitro endothelial 
cell growth and tubular morphogenesis 12.  
Neoangiogenic endothelial cells can be characterized in solid tumor by expression of CD105, a 
TGF-βR type III auxiliary receptor 13. In meningiomas, glioblastomas, and squamous cell 
carcinoma, CD105 expression on endothelial cells is related to neoangiogenesis and to tumor 
progression 14-16. CD105 is also expressed by endothelial cells in the primary central nervous system 
lymphomas and correlates with survival 17. 
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Here, we studied BCL2 and VEGFA expression in neoangiogenic endothelial cells and lymphoma 
cells in angioimmunoblastic T-cell lymphoma. 
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Design and Methods 
Patient selection 
30 patients with angioimmunoblastic T-cell lymphoma (14M/16F, 33-84 years, median 60 years), 
were included in this study. Histological diagnoses were established according to the WHO 
classification 18. Induction chemotherapy was six cycles of CHOP and CHOP-like regimen followed 
by consolidation and maintenance chemotherapies as previously reported 19. Eight age- and sex-
matched patients with lymph node hyperplasia were referred as controls. Approval was obtained 
from the Institut Universitaire d'Hématologie-Hôpital Saint-Louis institutional review board. All 
patients gave their informed consent. 
 
Tissue Specimen 
Lymph nodes, surgically removed for diagnostic purpose, were immediately cut: one part was fixed 
in formaldehyde and further processed for paraffin embedding, another part was snap-frozen. Bone 
marrow biopsies were performed in all 30 patients with angioimmunoblastic T-cell lymphoma, and 
skin biopsies in 11 patients with angioimmunoblastic T-cell lymphoma with skin rash. 
 
Microvessel density 
The microvessel density was evaluated by endothelial cell immunostaining with CD34 antibody 
(clone QBEnd10, Beckman Coulter). Angiogenesis assessment was based on the method of 
Weidner et al. 20 and international consensus criteria for angiogenesis quantification 21-22. 
Microvessels were counted at x400 magnification on five different fields. The microvessel density 
of each specimen was calculated as the mean value of the different counts. Five normal lymph 
nodes were used as controls for microvessel density measurement. 
MKI67 labelling index assessment 
MKI-67 labelling index was assessed using mouse monoclonal MIB1 antibody (Dako, France) with 
an indirect immunoperoxidase method. MKI-67 labelling index was calculated as the percentage of 
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positive nuclei for MKI67 staining at x400 magnification on five different fields. In the case of 
heterogeneous staining, areas containing the largest and smallest number of positive cells were 
selected and the percentages were averaged to give the MKI-67 labelling index. 
Triple Immunofluorescent Labelings 
Triple immunofluorescent labelings were performed to assess co-expression of BCL2/CD34/CD3 
and BCL2/CD34/VEGFA. Since three of the four primary antibodies were mouse antibodies of the 
IgG1 isotype, they each required binding to different fluorophores using Apex-Alexa or Zenon kits 
(Invitrogen, France). CD34 antibody (clone QBEnd10, Beckman Coulter) was thus bound with 
Apex to Alexa 594, BCL2 antibody (clone 124, Dako) with Apex to Alexa 488, and VEGFA 
antibody (clone 1316, Abcam) with Zenon to Alexa 350. CD3 antibody, a rabbit polyclonal 
antibody (Biocare Medical), was bound with Apex to Alexa 488. 
For further study of neoangiogenic CD105+ endothelial cells, triple BCL2/CD34/CD105 
immunofluorescent labeling was performed, with CD34 antibody bound with Apex to Alexa 594, 
BCL2 antibody bound with Apex to Alexa 488, and CD105 mouse antibody (clone SN6h, Abcam) 
bound with Zenon to Alexa 350. 
Tissue sections were analyzed by 2 different pathologists (AJ and PR) on a motorized Z-axis 
Olympus (Tokyo, Japan) BX 61 microscope. Microscopic pictures were captured through a UPlan 
Fl/40x/0.75 objective with a digital camera ColorView III using Olympus-SIS Cell F software. 
Laser-microdissection combined to molecular analyses 
Laser-microdissection was performed on 7µm-thick lymph node frozen sections after 
immunofluorescent staining; after acetone post-fixation 5 min at 4°C, sections were incubated for 5 
minutes with antibodies bound to fluorophores, using Zenon kits (Invitrogen, France). CD34 
antibody (clone QBEnd10, Beckman Coulter), CD105 (clone SN6h, Abcam), CD3 (rabbit 
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polyclonal, Biocare Medical) were bound to Alexa 488, and CD10 (clone 56C6, Novocastra) to 
Alexa 594. 
In the 30 angioimmunoblastic T-cell lymphoma lymph node sections, laser-microdissection was 
performed: i) for lymphoma cells, identified as CD3
+ 
CD10
+ 
medium-sized cells 23-25, ii) for CD34
+
 
endothelial cells, and iii) for CD105
+
 neoangiogenic endothelial cells, on different successive frozen 
sections. 
A quantitative assessment was achieved by PALM Robo software (Zeiss-Palm, Germany). For each 
patient, approximately 500 CD3
+
CD10
+ 
lymphoma cells corresponding to an average surface of 
170 000 µm², 500 CD34
+ 
endothelial cells, and 500 CD105
+
 neoangiogenic endothelial cells, 
corresponding to an average surface of 100 000µm², were microdissected and catapulted into tubes 
for RNA extraction. 
In the 8 lymph node hyperplasia frozen sections, laser-microdissection was performed to select: i) 
for CD3
+
 small-lymphocyte cells in interfollicular areas and ii) CD34
+
 endothelial cells, on different 
successive frozen sections. 
 Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA). First-strand cDNA was 
synthesized using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA) according to the 
manufacturer's instructions.  
Ascertainment of the specificity of laser microdissected cells was systematically performed using 
quantitative real-time PCR: 
- CD34
+
 microdissected cells from angioimmunoblastic T-cell lymphoma and lymph node 
hyperplasia were considered as endothelial cells since they expressed CD31 mRNA but not CD3ε 
or CD10 mRNA. 
- CD3
+
CD10
+
 microdissected cells from angioimmunoblastic T-cell lymphoma were considered as 
lymphoma cells since they expressed CD10 mRNA but not CD31 mRNA. 
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- CD3
+
 microdissected cells from lymph node hyperplasia were considered as lymphocytes since 
they expressed CD3ε but not CD31 mRNA. 
Quantitative real-time PCR was performed on an ABI PRISM 7700 system using the Pre-
Developed TaqMan Assay Reagent specific for human CD3ε (Hs01062241_m1), CD10 
(Hs00153510_m1), CD31 (Hs00169777_m1), BCL2 (Hs00608023_m1) and VEGFA 
(Hs00900055_m1), and for human transcription factor IID/TATA-binding protein (TBP) gene 
expression quantification (PE Applied Biosystems, UK). The TBP gene was used as an internal 
control. Results were quantified using the comparative cycle threshold (Ct) method. Jurkat and 
MCF7 cells, which respectively express the BCL2 and VEGFA genes, were used as calibrators 3, 26. 
CD3ε, CD10 and CD31 mRNA expressions were first assessed, to check the laser-microdissection 
selection of cell populations.  
 
Statistical Analyses 
Patient characteristics were compared using chi square and Fisher's exact tests for categorical 
variables, and Wilcoxon's test for continuous variables. Event-free survival was calculated from the 
date of diagnosis to the date of progression, relapse, or death. Overall survival was measured from 
the date of diagnosis to either death from any cause or the stopping date of January 1, 2008. 
Survival rates were estimated using the Kaplan–Meier method and compared by log-rank test. 
Multivariate survival analysis was performed using a Cox regression model. Difference were 
considered significant when the two-sided P-value was <0.05.  Difference were considered 
significant when the two-sided P-value was <0.05. All statistical analyses were performed using 
SAS 8.2 software (SAS Institute Inc, Cary, NC, USA). 
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Results 
BCL2 expression in AITL endothelial cells 
Using two different methods, multiple fluorescent immunostainings for BCL2 and CD34 (Figure 1), 
and laser-microdissection combined with molecular quantitative analyses (Figure 2, Table 1), we 
identified BCL2 protein in angioimmunoblastic T-cell lymphoma CD34
+ 
endothelial cells (Figure 
1) and showed a significantly higher expression of BCL2 mRNA in angioimmunoblastic T-cell 
lymphoma endothelial cells (3.27+/-0.31) than in lymph node hyperplasia endothelial cells (1.34+/-
0.17) (p=0.009). With the same methods used for laser-microdissected CD3
+
CD10
+ 
lymphoma 
cells, we showed a significantly higher expression of BCL2 mRNA in angioimmunoblastic T-cell 
lymphoma cells (28.34+/-2.34) than in lymph node hyperplasia CD3
+
 lymphocytes (17.47+/-1.07) 
(p=0.007).  
In the 30 patients with angioimmunoblastic T-cell lymphoma, 27.4+/-5.3% of CD34
+
 endothelial 
cells expressed CD105 neoangiogenic marker but were not detected in the eight patients with lymph 
node hyperplasia (Figure 3). 
With BCL2/CD34/CD105 triple immmunofluorescent labelling (Figures 4 and 5), in the 30 patients 
with angioimmunoblastic T-cell lymphoma, BCL2 was only identified in CD34
+
CD105
+
 
neoangiogenic endothelial cells (Figures 4 and 5). In these patients, 24.7+/-4.1% of CD34
+
 
endothelial cells were double positives for CD105 and BCL2 (Figure 3). 
 To get further insight into BCL2 expression by angioimmunoblastic T-cell lymphoma endothelial 
cells, CD105
+
 neoangiogenic endothelial cells were laser-microdissected and quantitative molecular 
analyses performed (Figure 6, Table 1). There was a significantly higher expression of BCL2 
mRNA in angioimmunoblastic T-cell lymphoma neoangiogenic CD105
+
endothelial cells (8.62+/-
2.87) than in laser-microdissected CD34
+
 endothelial cells (3.27+/-0.31) (p=0.027).  
in
se
rm
-0
06
82
93
1,
 v
er
sio
n 
1 
- 2
7 
M
ar
 2
01
2
Ratajczak et al. 
 11 
BCL2 and VEGFA coexpression in angioimmunoblastic T-cell lymphoma endothelial cells 
Using BCL2/VEGFA/CD34 triple immmunofluorescent labelling, we found a co-expression of 
BCL2 and VEGFA proteins in endothelial cells of angioimmunoblastic T-cell lymphoma (Figure 
1), but not of lymph node hyperplasia endothelial cells. 
Further qRT-PCR performed on laser-microdissected cells showed a significant difference of 
VEGFA mRNA expression i) between CD34
+ 
endothelial cells of angioimmunoblastic T-cell 
lymphoma and of lymph node hyperplasia (7.54+/-2.74 versus 2.99+/-0.79, p=0.023), and ii) 
between CD3
+
CD10
+ 
angioimmunoblastic T-cell lymphoma cells and CD3+lymph node 
hyperplasia lymphocytes (4.00+/-1.67 versus 0.51+/-0.06, p=0.012) (Table 1).  
The coexpression of BCL2 and VEGFA in endothelial cells of angioimmunoblastic T-cell 
lymphoma was also confirmed qRT-PCR of laser-microdissected cells. BCL2 and VEGFA mRNA 
levels were significantly related in endothelial cells of angioimmunoblastic T-cell lymphoma 
(R²=0.745, p<0.0001), but not of lymph node hyperplasia (R²=0.091, p=0.2572). Moreover, BCL2 
and VEGFA mRNA levels are not correlated in CD3
+
CD10
+ 
angioimmunoblastic T-cell lymphoma  
cells (R²=0.072, p=0.1602) (Figure 2C, D). 
AITL Endothelial BCL2 expression and tumor progression 
In the 30 angioimmunoblastic T-cell lymphoma cases (Table 1, Figure 7), endothelial BCL2 mRNA 
expression was not linked with proliferation index, but it was significantly related with i) 
microvessel density, ii) International Prognostic Index 27, iii) signs of tumor progression and 
extension (Bone marrow involvement, Ann Arbor Stage, elevated lactate dehydrogenase level). 
This contrasts with the absence of any clinical correlation with lymphoma cell BCL2 mRNA 
expression. 
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Further statistical analyses showed that BCL2 levels for CD34
+
 and CD105
+
 laser-microdissected 
angioimmunoblastic T-cell lymphoma endothelial cells correlated with the same clinical data. 
However the statistical significance was higher for CD105
+ 
neoangiogenic endothelial cells than for 
CD34
+ 
endothelial cells regarding i) microvessel density (R²=0.6412, p<0.0001 versus R²=0.5444, 
p=0.0017) (Figure 7) , ii) International Prognostic Index (p<0.0001 versus p=0.0002), iii) signs of 
tumor progression and extension (Bone marrow involvement (p<0.0001 versus p=0.0004), Ann 
Arbor Stage (p=0.0006 versus p=0.0018), elevated lactate dehydrogenase level (p=0.0094 versus 
p=0.0397).  
 
Within a median follow-up of 61 months, 17 patients (56%) relapsed and 16 of them (53%) died. 
The 2-year EFS and OS rate were, respectively, 41.3 and 72.9%, with median EFS and OS at 18.5 
and 39 months. Poor EFS and OS were correlated with high BCL2 levels, in microdissected CD34
+
 
endothelial cells (p=0.0129 and 0.0231, respectively) and in microdissected CD34
+
CD105
+
 
neoangiogenic endothelial cells (p=0.0092 and 0.0104, respectively) but not in microdissected 
CD3
+
CD10
+
 lymphoma cells (p=0.0612 and 0.0783, respectively). 
Multivariate analyses revealed that BCL2 levels in microdissected CD34+CD105+ neoangiogenic 
endothelial cells were independent adverse prognostic factors for event-free survival and overall 
survival (P=0.0091 and 0.0145, respectively). in
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Discussion 
We showed the coexpression of BCL2 and VEGFA in endothelial and lymphoma cells of 
angioimmunoblastic T-cell lymphoma, and the significant relation of BCL2 expression in 
neoangiogenic endothelial cells with microvessel density, International Prognostic Index, and signs 
of tumor progression. 
BCL2 overexpression is a hallmark of follicular lymphoma cells 28. It has also been reported in 
lymphoma cells of few angioimmunoblastic T-cell lymphoma 29. However, BCL2 overexpression in 
endothelial cells has not been reported so far in angioimmunoblastic T-cell lymphoma.  
The role of BCL2 in endothelial cells has been demonstrated by experimental studies. The specific 
blocking of BCL2 activity by anti-BCL2 antisense G3139, alters in vitro endothelial cell growth 
and tubular morphogenesis 12. In BCL2 deficient mice, isolated retinal endothelial cells have 
reduced capacities of migration, tenascin-C expression, and adhesion to vitronectin and fibronectin. 
They also fail to form capillaries in Matrigel 30. On the contrary, experimental induction of BCL2 
overexpression in HDMEC endothelial cells results in an enhanced angiogenic phenotype 31. BCL2-
transduction in HUVEC endothelial cells induces the formation of chimeric vessels, and 
arteriogenic remodeling in immunodeficient mice 32. Moreover, the antiapoptotic activities of BCL2 
correlate with vascular maturation and transcriptional modulation of HUVEC endothelial cells 33. 
BCL2 and VEGFA proteins were coexpressed in endothelial and lymphoma cells of the 30 
angioimmunoblastic T-cell lymphoma cases we studied. However, a significant relation between 
BCL2 and VEGFA mRNA levels was only found in endothelial cells. Controls with laser-
microdissected endothelial cells from lymph node hyperplasia showed that this correlation between 
BCL2 and VEGFA mRNA levels was specific for angioimmunoblastic T-cell lymphoma 
endothelial cells. Such a correlation for endothelial cells but not for tumor cells has also been 
identified in oral squamous cell carcinoma 8, 34, where in vitro studies further demonstrated that 
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BCL2 expression level in endothelial cells controls VEGFA expression in tumor cells 8. In 
xenografted squamous cell carcinoma cell lines, BCL2 cross-talk between endothelial and tumor 
cells through VEGFA leads to tumor growth and metastatic development 8-9, 11, 35.  
A neoangiogenic subtype of endothelial cells, expressing CD105, a TGFβ-Receptor type III 
auxiliary receptor 13, has been identified 36-38. CD105 expression on endothelial cells is related to 
tumor progression in squamous cell carcinoma 16, glioblastomas 15 and meningiomas 14. It correlates 
with survival in primary central nervous system lymphomas 17. In our study using immunostainings 
and laser-microdissection combined with molecular analyses, we demonstrate that in 
angioimmunoblastic T-cell lymphoma, only CD34
+
CD105
+ 
neoangiogenic endothelial cells 
expressed BCL2.  
The fact that BCL2 expression by these neoangiogenic endothelial cells is significantly related with 
microvessel density in the 30 angioimmunoblastic T-cell lymphoma cases we studied is coherent 
with the role of VEGFA production by endothelial cells in tumoral angiogenesis 39. The further 
significant relations of BCL2 expression by neoangiogenic endothelial with International Prognostic 
Index and signs of tumor extension, as well as an independent prognostic factor also underline the 
role of angiogenesis in lymphoma progression, a fact recently identified by stromal gene signatures 
in large-B-cell lymphomas 40.  Tumor development is characterized by a defective control of cellular 
homeostasis. The neoangiogenic endothelial BCL2 positives relations with International prognostic 
Index and signs of tumor extension, as well as an independent prognostic factor, and the absence of 
relation with the global Proliferation Index (i.e. stromal and tumoral cells) can be interpreted as an 
anti-apoptotic action of neoangiogenic endothelial BCL2 on lymphoma cells. 
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Figure Legends and Table 
 
Figure 1 
BCL2 and VEGF expression in endothelial cells of angioimmunoblastic T-cell lymphoma.  
Co-expression of BCL2, VEGFA on angioimmunoblastic T-cell lymphoma CD34
+
 endothelial cells 
(Triple immunofluorescent staining: BCL2 in red, VEGFA in blue and CD34 in green). 
Figure 2 
A) Molecular evaluation of laser-microdissected CD34
+
 cells in angioimmunoblastic T-cell 
lymphoma: they express CD31 and not CD10, thus confirming the molecular profile of endothelial 
cells (left). 
Molecular evaluation of laser-microdissected CD3
+
CD10
+
 cells in angioimmunoblastic T-cell 
lymphoma: they express CD10 and not CD31, thus confirming the molecular profile of lymphoma 
cells (right). 
B) Molecular evaluation of laser-microdissected CD34
+
 cells in lymph node hyperplasia: they 
express CD31 and not CD10, thus confirming the molecular profile of endothelial cells (left). 
Molecular evaluation of laser-microdissected CD3
+ 
cells in lymph node hyperplasia: they express 
CD3ε and not CD31, thus confirming the molecular profile of lymphocytes (right). 
C) The expression of BCL2 mRNA in laser-microdissected CD34
+
 angioimmunoblastic T-cell 
lymphoma endothelial cells is significantly correlated with VEGFA mRNA expression levels in the 
same laser-microdissected cell population (left). BCL2 and VEGFA mRNA expression levels are 
not correlated in the same laser-microdissected cell population of CD3
+
CD10
+ 
lymphoma cells of 
angioimmunoblastic T-cell lymphoma (right). 
D) In lymph node hyperplasia controls, no correlations are found between BCL2 and VEGFA 
mRNA expression levels whether for laser-microdissected CD34
+
 cells (left) or for laser-
microdissected CD3
+
 lymphocytes (right).  
 
Figure 3  
Proportion of endothelial cells expressing CD105 neoangiogenic marker and BCL2 in the 30 
patients with angioimmunoblastic T-cell lymphoma and in the 8 patients with lymph node 
hyperplasia. 
 
Figure 4 
BCL2 expression in CD105
+
 neoangiogenic endothelial cells of angioimmunoblastic T-cell 
lymphoma.  
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In the CD34+ angioimmunoblastic T-cell lymphoma endothelial population, BCL2 is co-expressed 
with CD105, a marker of neoangiogenic endothelial cells (Triple immunofluorescent staining: 
CD34 in red, CD105 in blue and BCL2 in green). 
 
Figure 5 
Absence of BCL2 expression in CD105
-
 neoangiogenic endothelial cells of angioimmunoblastic T-
cell lymphoma.  
No co-expression of BCL2 is found in angioimmunoblastic T-cell lymphoma areas where CD34
+
 
endothelial cells do not express CD105 (Triple immunofluorescent staining: CD34 in red, CD105 in 
blue and BCL2 in green). 
 
Figure 6 
A) Molecular evaluation of laser-microdissected CD105
+
 cells in angioimmunoblastic T-cell 
lymphoma: they express CD31 and not CD10, thus confirming the molecular profile of endothelial 
cells. 
B) The expression of BCL2 mRNA in laser-microdissected CD105
+
 endothelial cells of 
angioimmunoblastic T-cell lymphoma is significantly correlated with VEGFA mRNA expression 
levels in the same laser-microdissected cell population. 
 
Figure 7 
BCL2 in endothelial cells, microvascular density and proliferation index. 
A) In microdissected CD34
+
 endothelial cells from angioimmunoblastic T-cell lymphoma lymph 
node, BCL2 mRNA expression level is significantly correlated with microvessel density (left). In 
CD105
+
 neoangiogenic endothelial cells of angioimmunoblastic T-cell lymphoma, BCL2 mRNA 
expression is highly related with microvessel density. 
In contrast, BCL2 CD34
+
 endothelial mRNA level is not correlated with microvascular density in 
reantive lymph node hyperplasia. 
B) In AITL, CD34
+
 endothelial as well as CD105
+
 neoangiogenic endothelial cell BCL2 mRNA 
levels are not correlated with KI-67 proliferating index. In CD34
+
 endothelial cells of lymph node 
hyperplasia, no correlation was observed either. 
 
Table 1 
BCL2 and VEGFA gene expression in microdissected CD34
+
 or CD105
+
 endothelial and 
microdissected CD3
+
CD10
+
 lymphoma cells according to clinical and biological characteristics in 
angioimmunoblastic T-cell lymphoma patients (n=30) 
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